<Disease><Name>ASPARTYLGLUCOSAMINURIA (AGU)</Name><Synonym>ASPARTYLGLUCOSAMINIDASE DEFICIENCY; AGA DEFICIENCY</Synonym><OMIM><Number>208400</Number><URL>http://omim.org/entry/208400</URL></OMIM><Orphanet><Number>93</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=93</URL></Orphanet><Protein><Number>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</Number><URL>http://www.uniprot.org/uniprot/P20933</URL></Protein><ExPASy><Number>3.5.1.26</Number><URL>http://enzyme.expasy.org/EC/3.5.1.26</URL></ExPASy><Gene>4q34.3Detail information to gene locus by the National Center for Biotechnology Information NCBI:

Aspartylglucosaminidase
</Gene><ICD>E77.1</ICD><Summary>rare (~100 cases) ;autosomal recessive ;mutation in the AGA gene ;most of patients were found in Finland</Summary><Symptoms><symtomp><id>2604</id><symptom>acne</symptom><category>SKIN</category></symtomp><symtomp><id>2341</id><symptom>angiokeratoma</symptom><category>CARDIOVASCULAR SYSTEM | SKIN</category></symtomp><symtomp><id>1803</id><symptom>anteverted nostril</symptom><category>HEAD</category></symtomp><symtomp><id>3822</id><symptom>brachycephaly</symptom><category>HEAD</category></symtomp><symtomp><id>2104</id><symptom>cardiomyopathy</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3677</id><symptom>cardiomyopathy, hypertrophic</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2226</id><symptom>cerebral atrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3377</id><symptom>clubfoot</symptom><category>SKELETAL DEFECT</category></symtomp><symtomp><id>1949</id><symptom>clumsiness, coordination defect or unsteadiness</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1761</id><symptom>coarse facial features</symptom><category>HEAD</category></symtomp><symtomp><id>1982</id><symptom>diarrhea</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2302</id><symptom>dysostosis multiplex</symptom><category>SKELATAL DEFECT</category></symtomp><symtomp><id>2449</id><symptom>heart involvement</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2428</id><symptom>hernia</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1896</id><symptom>hypertonia, spasticity</symptom><category>MUSCLES</category></symtomp><symtomp><id>3913</id><symptom>infections (respiratory tract/system)</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>1715</id><symptom>infections (severe or recurrent)</symptom><category>GENERAL TOPICS | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1813</id><symptom>large or wide mouth</symptom><category>HEAD</category></symtomp><symtomp><id>2603</id><symptom>lens opacities</symptom><category>EYES</category></symtomp><symtomp><id>1852</id><symptom>macroglossia, large/protuding tongue</symptom><category>HEAD</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1886</id><symptom>microcephaly (&lt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2038</id><symptom>neutropenia (decreased neutrophils)</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM | LABORATORY FINDINGS</category></symtomp><symtomp><id>2340</id><symptom>normal at birth</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2012</id><symptom>photophobia or photosensitive defect in light-exposed area</symptom><category>SKIN</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2109</id><symptom>short stature</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2342</id><symptom>skeletal changes, skeletal abnormalities</symptom><category>SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>2250</id><symptom>skoliosis, kyphoskoliosis</symptom><category>BODY | SKELATAL DEFECT</category></symtomp><symtomp><id>1874</id><symptom>speech development, delayed, abnormal</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2042</id><symptom>splenomegaly (large spleen)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>996</id><name>4-N-2-acetamido-2-deoxy-beta-D-glucopyrasonyl-L-asparagine</name><specimen>urine</specimen><value>increased</value><min>    </min><max>    </max><unit>not detectable</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>995</id><name>Aspartylglucosamine</name><specimen>urine</specimen><value>increased</value><min>0.20</min><max>1.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>965</id><name>Oligosaccharides</name><specimen>urine</specimen><value>abnormal</value><min>    </min><max>    </max><unit>not detectable</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>6945</id><title>Detailed Profile of Cognitive Dysfunction in Children with Aspartylglucosaminuria</title><author>Harjunen E,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>5166</id><title>Aspartylglucosaminuria caused by a novel homozygous mutation in the AGA gene was identified by an exome-first approach in a pat</title><author>Yamamoto T,</author><journal>Brain Dev</journal><year>2017</year><book /><volume>39</volume><number>5</number><pages>422-425</pages><co_aut>et al.</co_aut></literature><literature><id>5167</id><title>White Matter Microstructure and Subcortical Gray Matter Structure Volumes in Aspartylglucosaminuria; a 5-Year Follow-up Brain M</title><author>Anna T,</author><journal>JIMD Rep</journal><year>2017</year><book /><volume>35</volume><number>0</number><pages>105-115</pages><co_aut>et al.</co_aut></literature><literature><id>5168</id><title>Brain MRI findings in two Turkish pediatric patients with aspartylglucosaminuria</title><author>Kartal A,</author><journal>Neuroradiol J</journal><year>2016</year><book /><volume>29</volume><number>5</number><pages>310-313</pages><co_aut>Ayd&#305;n K</co_aut></literature><literature><id>8049</id><title>Aspartylglycosaminuria: A Review</title><author>Arvio M</author><journal>Orphanet J Rare Dis</journal><year>2016</year><book /><volume>11</volume><number>1</number><pages>162</pages><co_aut /></literature><literature><id>3661</id><title>Brain MRI findings in aspartylglucosaminuria</title><author>Tokola AM,</author><journal>J Neuroradiol</journal><year>2015</year><book /><volume>42</volume><number>6</number><pages>345-357</pages><co_aut>Aberg LE, Autti TH</co_aut></literature><literature><id>3662</id><title>Structural basis of a point mutation that causes the genetic disease aspartylglucosaminuria</title><author>Sui L,</author><journal>Structure</journal><year>2014</year><book /><volume>22</volume><number>12</number><pages>1855-1861</pages><co_aut>et al.</co_aut></literature><literature><id>3663</id><title>Aspartylglucosaminuria: unusual neonatal presentation in Qatari twins with a novel aspartylglucosaminidase gene mutation and 3 </title><author>Opladen T,</author><journal>J Child Neurol</journal><year>2014</year><book /><volume>29</volume><number>1</number><pages>36-42</pages><co_aut>et al.</co_aut></literature><literature><id>2917</id><title>Sleep-related hypermotor seizures in aspartylglucosaminuria: a case report</title><author>Ambrosetto G</author><journal>Epilepsia</journal><year>2009</year><book /><volume>50</volume><number>6</number><pages>1638-1640</pages><co_aut>Santucci M</co_aut></literature><literature><id>2918</id><title>Structural basis of aspartylglucosaminuria</title><author>Saito S</author><journal>Biochem Biophys Res Commun</journal><year>2008</year><book /><volume>377</volume><number>4</number><pages>1168-1172</pages><co_aut>et al.</co_aut></literature><literature><id>1656</id><title>Dysmorphic facial features in aspartylglucosaminuria patients and carriers</title><author>Arvio MA</author><journal>Clin Dysmorphol</journal><year>2004</year><book /><volume>13</volume><number>1</number><pages>11-15</pages><co_aut>et al.</co_aut></literature><literature><id>1657</id><title>Startle epilepsy complicating aspartylglucosaminuria</title><author>Labate A</author><journal>Brain Dev</journal><year>2004</year><book /><volume>26</volume><number>2</number><pages>130-133</pages><co_aut>et al.</co_aut></literature><literature><id>1658</id><title>Autoproteolytic activation of human aspartylglucosaminidase</title><author>Saarela J</author><journal>Biochem J</journal><year>2004</year><book /><volume>378</volume><number>2</number><pages>363-371</pages><co_aut>et al.</co_aut></literature><literature><id>1396</id><title>Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosoma</title><author>Harkke S</author><journal>J Gene Med</journal><year>2003</year><book /><volume>5</volume><number>6</number><pages>472-482</pages><co_aut>Laine M, Jalanko A</co_aut></literature><literature><id>1659</id><title>Progressive nature of aspartylglucosaminuria</title><author>Arvio P</author><journal>Acta Paediatr</journal><year>2002</year><book /><volume>91</volume><number>3</number><pages>255-257</pages><co_aut>Arvio M</co_aut></literature><literature><id>1241</id><title>Bone marrow transplantation for aspartylglucosaminuria: follow-up study of transplanted and non-transplanted patients</title><author>Arvio M</author><journal>J Pediatr</journal><year>2001</year><book /><volume>138</volume><number>2</number><pages>288-290</pages><co_aut>Sauna-Aho O, Peippo M</co_aut></literature><literature><id>1395</id><title>Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations</title><author>Saarela J</author><journal>Hum Mol Genet</journal><year>2001</year><book /><volume>10</volume><number>9</number><pages>983-995</pages><co_aut>et al.</co_aut></literature><literature><id>1242</id><title>Bone marrow transplantation in aspartylglucosaminuria--histopathological and MRI study</title><author>Autti T</author><journal>Neuropediatrics</journal><year>1999</year><book /><volume>60</volume><number>6</number><pages>283-288</pages><co_aut>et al.</co_aut></literature><literature><id>97</id><title>Disorders of glycoprotein degradation and structure: alpha-mannosidosis, beta-mannosidosis, fucosidosis, sialidosis, aspartylglucosminuria and carbohydrate- deficient glycoprotein syndrome</title><author>Thomas GH</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>0</number><pages>2529-2561</pages><co_aut>Beaudet AL</co_aut></literature><literature><id>339</id><title>Quantitative determination of 4-N-2-acetamido-2-deoxy-&#223;-D-glucopyrasonyl-L-asparagine in the urine of patients with aspartylglyc</title><author>Maury P</author><journal>J Lab Clin Med</journal><year>1979</year><book /><volume>93</volume><number>0</number><pages>718</pages><co_aut /></literature></Literatures></Disease>